202737-28-8

Basic information

• Product Name: 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid
• Synonyms: 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid;1-(1,3-BENZODIOXOL-5-YL)-CYCLOBUTANECARBOXYLIC ACID;1-(BENZO[D][1,3]DIOXOL-6-YL)CYCLOBUTANECARBOXYLIC ACID
• CAS NO: 202737-28-8
• Molecular Formula: C12H12O4
• Molecular Weight: 220.223
• Mol File: 202737-28-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid(202737-28-8)
• EPA Substance Registry System: 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid(202737-28-8)

Safety Data

• Hazardous Substances Data: 202737-28-8(Hazardous Substances Data)

Usage

Chemical class

Cyclobutane derivative containing a benzodioxole ring

Molecular weight

232.236 g/mol

Potential applications

Pharmaceutical industry
Anti-inflammatory properties
Analgesic properties
Development of new drugs in medicinal chemistry

Chemical structure

Interesting candidate for further research and development in the pharmaceutical industry
These properties highlight the importance of 1-(2H-1,3-benzodioxol-5-yl)cyclobutane-1-carboxylic acid as a potential compound for pharmaceutical applications, particularly in the development of anti-inflammatory and analgesic drugs. Its unique chemical structure also makes it a promising candidate for further research in the field of medicinal chemistry.

Relevant articles and documents

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation

PCT No. PCT/SE97/01310 Sec. 371 Date Apr. 12, 1999 Sec. 102(e) Date Apr. 12, 1999 PCT Filed Jul. 23, 1997 PCT Pub. No. WO98/04517 PCT Pub. Date Feb. 5, 1998This invention relates to the use of 2-(diisopropylamino)-ethyl-1-phenyl-cyclopentane-carboxylate or 2-(diisopropylamino)-ethyl-1-phenyl-cyclohexane-carboxylate, or a pharmaceutically accceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome (IBS).